Encephalomyelitis, Autoimmune, Experimental

It is experimentally induced rather than naturally occurring. The grounding describes induction by inoculation with white matter emulsion combined with Freund's adjuvant, myelin basic protein, or purified central myelin, and also by passive immunization with T cells from an afflicted animal. These triggers provoke a T cell-mediated immune response directed against central myelin.

The disease is driven by a T cell-mediated autoimmune response against central myelin. This leads to inflammatory lesions and demyelination in the CNS, including perivascular and periventricular foci of inflammation and demyelination, with subpial demyelination beneath meningeal infiltrates also described. The literature also notes associated axonal loss, gliosis, and counter-regulatory processes such as resolution of inflammation and remyelination.

As an experimental model, the main factors associated with disease occurrence are the inducing interventions used in research. These include exposure to myelin-containing preparations, myelin basic protein, purified central myelin, Freund's adjuvant, or transfer of encephalitogenic T cells. The supplied grounding does not support additional intrinsic risk factors.

There is no standard clinical care described for this experimental animal model. In the literature, EAE is used to study and validate therapies relevant to multiple sclerosis, including drugs and immune-modulating approaches at the modality or drug-class level. The grounding supports its use in therapy research rather than a treatment regimen for the model itself.